Literature DB >> 12547602

Liposomes and ISCOMs.

Gideon F A Kersten1, Daan J A Crommelin.   

Abstract

Liposomes and ISCOMs have a long history as vehicles for antigen delivery. Liposomes can carry both membrane associated antigens as well as water soluble molecules. Their physical properties are highly variable, depending on composition and manufacturing method. This allows optimised design for specific tasks (targeting, co-incorporation of adjuvants, etc.). ISCOMs already have a build-in adjuvant, Quillaja saponin, which is a structural part of the vehicle. In recent years, considerable progress has been achieved with respect to the use of better defined saponin. Clinical trials with ISCOMs are in progress and registered liposomal vaccines exist. Here, follows a brief overview on recent developments with emphasis on pharmaceutical aspects.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12547602     DOI: 10.1016/s0264-410x(02)00540-6

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  20 in total

1.  Novel catanionic surfactant vesicle vaccines protect against Francisella tularensis LVS and confer significant partial protection against F. tularensis Schu S4 strain.

Authors:  Katharina Richard; Barbara J Mann; Lenea Stocker; Eileen M Barry; Aiping Qin; Leah E Cole; Matthew T Hurley; Robert K Ernst; Suzanne M Michalek; Daniel C Stein; Philip Deshong; Stefanie N Vogel
Journal:  Clin Vaccine Immunol       Date:  2013-12-18

2.  Preparation and characterization of nickel nanoparticles for binding to his-tag proteins and antigens.

Authors:  Jigna D Patel; Ronan O'Carra; Julia Jones; Jerold G Woodward; Russell J Mumper
Journal:  Pharm Res       Date:  2006-12-19       Impact factor: 4.200

3.  Biodegradable Viral Nanoparticle/Polymer Implants Prepared via Melt-Processing.

Authors:  Parker W Lee; Sourabh Shukla; Jaqueline D Wallat; Chaitanya Danda; Nicole F Steinmetz; Joao Maia; Jonathan K Pokorski
Journal:  ACS Nano       Date:  2017-09-13       Impact factor: 15.881

Review 4.  Rationalizing the development of live attenuated virus vaccines.

Authors:  Adam S Lauring; Jeremy O Jones; Raul Andino
Journal:  Nat Biotechnol       Date:  2010-06-07       Impact factor: 54.908

Review 5.  The ABC of clinical and experimental adjuvants--a brief overview.

Authors:  Richard Brunner; Erika Jensen-Jarolim; Isabella Pali-Schöll
Journal:  Immunol Lett       Date:  2009-11-04       Impact factor: 3.685

6.  Novel Injectable Pentablock Copolymer Based Thermoresponsive Hydrogels for Sustained Release Vaccines.

Authors:  Sharan Bobbala; Viral Tamboli; Arlene McDowell; Ashim K Mitra; Sarah Hook
Journal:  AAPS J       Date:  2015-11-20       Impact factor: 4.009

7.  Efficiency of pH-sensitive fusogenic polymer-modified liposomes as a vaccine carrier.

Authors:  Shinobu Watarai; Tana Iwase; Tomoko Tajima; Eiji Yuba; Kenji Kono
Journal:  ScientificWorldJournal       Date:  2013-02-04

8.  Archaeosome adjuvant overcomes tolerance to tumor-associated melanoma antigens inducing protective CD8 T cell responses.

Authors:  Lakshmi Krishnan; Lise Deschatelets; Felicity C Stark; Komal Gurnani; G Dennis Sprott
Journal:  Clin Dev Immunol       Date:  2011-01-18

Review 9.  Immunopotentiating and Delivery Systems for HCV Vaccines.

Authors:  Alexander K Andrianov; Thomas R Fuerst
Journal:  Viruses       Date:  2021-05-25       Impact factor: 5.048

Review 10.  Malaria vaccine adjuvants: latest update and challenges in preclinical and clinical research.

Authors:  Elena Mata; Aiala Salvador; Manoli Igartua; Rosa María Hernández; José Luis Pedraz
Journal:  Biomed Res Int       Date:  2013-04-23       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.